RELAFEN
LOE ApproachingNDAORALTABLET
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
RELAFEN by GSK is clinical pharmacology nabumetone is a non-steroidal anti-inflammatory drug (nsaid) that exhibits anti-inflammatory, analgesic, and antipyretic properties in pharmacologic studies. First approved in 1991.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Relafen (nabumetone) is a non-steroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis to provide anti-inflammatory, analgesic, and antipyretic effects. It is a prodrug that undergoes hepatic conversion to its active metabolite 6-methoxy-2-naphthylacetic acid (6MNA). The drug is indicated for conditions requiring NSAID therapy, primarily inflammatory and pain management in patients who can tolerate oral administration.
LOE Approaching
With LOE approaching and 30% competitive pressure, the brand team is likely in maintenance mode with reduced headcount and focus on competitive positioning against other NSAIDs.
Mechanism of Action
CLINICAL PHARMACOLOGY Nabumetone is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic properties in pharmacologic studies. As with other non-steroidal anti-inflammatory agents, its mode of action is not known; however, the ability to inhibit…
Worked on RELAFEN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.